• Login
    View Item 
    •   Home
    • 1 Published Research and Commentary
    • Mental Health
    • View Item
    •   Home
    • 1 Published Research and Commentary
    • Mental Health
    • View Item
    Apr 12, 2021
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browse

    All of MSFTitleAuthorsSubjectsPublisherJournalThis CollectionTitleAuthorsSubjectsPublisherJournal

    Positive Outcomes of HAART at 24 Months in HIV-Infected Patients in Cambodia.

    • CSV
    • RefMan
    • EndNote
    • BibTex
    • RefWorks
    Thumbnail
    Name:
    Positive outcomes of HAART- AIDS ...
    Size:
    139.0Kb
    Format:
    PDF
    Download
    Authors
    Ferradini, L
    Laureillard, D
    Prak, N
    Ngeth, C
    Fernandez, M
    Pinoges, L
    Puertas, G
    Taburet, A
    Ly, N
    Rouzioux, C
    Balkan, S
    Quillet, C
    Delfraissy, J F
    Show allShow less
    Affiliation
    Epicentre, Paris, France. msffr.comed@online.com.kh
    Issue Date
    2007-11-12
    
    Metadata
    Show full item record
    Journal
    AIDS
    Abstract
    OBJECTIVES: African and Asian cohort studies have demonstrated the feasibility and efficacy of HAART in resource-poor settings. The long-term virological outcome and clinico-immunological criteria of success remain important questions. We report the outcomes at 24 months of antiretroviral therapy (ART) in patients treated in a Médecins Sans Frontières/Ministry of Health programme in Cambodia. METHODS: Adults who started HAART 24 +/- 2 months ago were included. Plasma HIV-RNA levels were assessed by real-time polymerase chain reaction. Factors associated with virological failure were analysed using logistic regression. RESULTS: Of 416 patients, 59.2% were men; the median age was 33.6 years. At baseline, 95.2% were ART naive, 48.9% were at WHO stage IV, and 41.6% had a body mass index less than 18 kg/m. The median CD4 cell count was 11 cells/microl. A stavudine-lamivudine-efavirenz-containing regimen was initiated predominantly (81.0%). At follow-up (median 23.8 months), 350 (84.1%) were still on HAART, 53 (12.7%) had died, six (1.4%) were transferred, and seven (1.7%) were lost to follow-up. Estimates of survival were 85.5% at 24 months. Of 346 tested patients, 259 (74.1%) had CD4 cell counts greater than 200 cells/microl and 306 (88.4%) had viral loads of less than 400 copies/ml. Factors associated with virological failure at 24 months were non-antiretroviral naive, an insufficient CD4 cell gain of less than 350 cells/microl or a low trough plasma ART concentration. In an intention-to-treat analysis, 73.6% of patients were successfully treated. CONCLUSION: Positive results after 2 years of advanced HIV further demonstrate the efficacy of HAART in the medium term in resource-limited settings.
    URI
    http://hdl.handle.net/10144/19977
    DOI
    10.1097/QAD.0b013e32828cc8b7
    PubMed ID
    18090277
    Language
    en
    ISSN
    0269-9370
    ae974a485f413a2113503eed53cd6c53
    10.1097/QAD.0b013e32828cc8b7
    Scopus Count
    Collections
    Mental Health

    entitlement

    Related articles

    • Immunological and virological responses to highly active antiretroviral therapy in a non-clinical trial setting in a developing Caribbean country.
    • Authors: Kilaru KR, Kumar A, Sippy N, Carter AO, Roach TC
    • Issue date: 2006 Mar
    • Response to highly active antiretroviral therapy among severely immuno-compromised HIV-infected patients in Cambodia.
    • Authors: Madec Y, Laureillard D, Pinoges L, Fernandez M, Prak N, Ngeth C, Moeung S, Song S, Balkan S, Ferradini L, Quillet C, Fontanet A
    • Issue date: 2007 Jan 30
    • Scaling up of highly active antiretroviral therapy in a rural district of Malawi: an effectiveness assessment.
    • Authors: Ferradini L, Jeannin A, Pinoges L, Izopet J, Odhiambo D, Mankhambo L, Karungi G, Szumilin E, Balandine S, Fedida G, Carrieri MP, Spire B, Ford N, Tassie JM, Guerin PJ, Brasher C
    • Issue date: 2006 Apr 22
    • Generic fixed-dose combination antiretroviral treatment in resource-poor settings: multicentric observational cohort.
    • Authors: Calmy A, Pinoges L, Szumilin E, Zachariah R, Ford N, Ferradini L, Médecins Sans Frontieres.
    • Issue date: 2006 May 12
    • Efficacy and safety of indinavir/ritonavir 400/100 mg twice daily plus two nucleoside analogues in treatment-naive HIV-1-infected patients with CD4+ T-cell counts <200 cells/mm3: 96-week outcomes.
    • Authors: Mootsikapun P, Chetchotisakd P, Anunnatsiri S, Boonyaprawit P
    • Issue date: 2005
    DSpace software (copyright © 2002 - 2021)  DuraSpace
    Quick Guide | Contact Us
    Open Repository is a service operated by 
    Atmire NV
     

    Export search results

    The export option will allow you to export the current search results of the entered query to a file. Different formats are available for download. To export the items, click on the button corresponding with the preferred download format.

    By default, clicking on the export buttons will result in a download of the allowed maximum amount of items.

    To select a subset of the search results, click "Selective Export" button and make a selection of the items you want to export. The amount of items that can be exported at once is similarly restricted as the full export.

    After making a selection, click one of the export format buttons. The amount of items that will be exported is indicated in the bubble next to export format.